Review



murine recombinant il17a  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems murine recombinant il17a
    In vitro efficacy of Affibody molecules in blocking <t>IL17A</t> induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Murine Recombinant Il17a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 31 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine recombinant il17a/product/R&D Systems
    Average 93 stars, based on 31 article reviews
    murine recombinant il17a - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice"

    Article Title: Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

    Journal: Frontiers in Cardiovascular Medicine

    doi: 10.3389/fcvm.2022.831039

    In vitro efficacy of Affibody molecules in blocking IL17A induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Figure Legend Snippet: In vitro efficacy of Affibody molecules in blocking IL17A induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).

    Techniques Used: In Vitro, Blocking Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Recombinant, Control

    Effect of Affibody molecule targeting IL17A in atherosclerotic lesion development in ApoE −/− mice. Quantification of lesion size (%) in the aortic arch (A) and brachiocephalic artery (B) of control mice and αIL17A Affibody molecule treated mice. Quatification of lesion areas (μm 2 ) in the aortic root (C) . Representative Oil Red O immunostainings from the aortic root of control (D) and mice treated with αIL17A Affibody molecule (E) . Data are presented as Median with IQR.
    Figure Legend Snippet: Effect of Affibody molecule targeting IL17A in atherosclerotic lesion development in ApoE −/− mice. Quantification of lesion size (%) in the aortic arch (A) and brachiocephalic artery (B) of control mice and αIL17A Affibody molecule treated mice. Quatification of lesion areas (μm 2 ) in the aortic root (C) . Representative Oil Red O immunostainings from the aortic root of control (D) and mice treated with αIL17A Affibody molecule (E) . Data are presented as Median with IQR.

    Techniques Used: Control

    Blood and morphometric parameters <xref ref-type= a and T cell subsets in spleen b ." title=" Blood and morphometric parametersa and T cell subsets in spleenb. " property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Blood and morphometric parameters a and T cell subsets in spleen b .

    Techniques Used: Control

    Affibody molecule against IL17A reduces plasma levels of inflammatory and/or atherosclerosis-associated proteins in ApoE −/− mice. The Volcano plot shows fold changes (FC) and p -values of differentially altered plasma proteins analyzed by olink proteomics, in mice treated with αIL17A Affibody molecule ( n = 11) compared to sham ( n = 12) (A) . The p -values are presented on log10 scale while the FCs were calculated from linearized normalized protein expression (NPX) values and presented on log2 scale. Positive log2 fold change values correspond to higher protein levels and negative values correspond to reduced protein levels in mice treated with αIL17A Affibody molecule. The horizontal dotted line reflects the cut-off for statistical significance ( p < 0.05). Blue circles highlight proteins with a significant decrease ( p < 0.05) and red circles highlight proteins with a significant increase ( p < 0.05). Gray circles represent proteins with no statistical significance. Correlation between the plasma concentration of CXCL1 protein and the area of aortic root lesion in atherosclerotic prone ApoE −/− mice ( n = 8) (B) .
    Figure Legend Snippet: Affibody molecule against IL17A reduces plasma levels of inflammatory and/or atherosclerosis-associated proteins in ApoE −/− mice. The Volcano plot shows fold changes (FC) and p -values of differentially altered plasma proteins analyzed by olink proteomics, in mice treated with αIL17A Affibody molecule ( n = 11) compared to sham ( n = 12) (A) . The p -values are presented on log10 scale while the FCs were calculated from linearized normalized protein expression (NPX) values and presented on log2 scale. Positive log2 fold change values correspond to higher protein levels and negative values correspond to reduced protein levels in mice treated with αIL17A Affibody molecule. The horizontal dotted line reflects the cut-off for statistical significance ( p < 0.05). Blue circles highlight proteins with a significant decrease ( p < 0.05) and red circles highlight proteins with a significant increase ( p < 0.05). Gray circles represent proteins with no statistical significance. Correlation between the plasma concentration of CXCL1 protein and the area of aortic root lesion in atherosclerotic prone ApoE −/− mice ( n = 8) (B) .

    Techniques Used: Expressing, Concentration Assay

    Effects of Affibody molecule against IL17A on gene expression in splenocytes and thoracic aorta from ApoE −/− mice. mRNA levels were assessed by quantitative real-time reverse transcription polymerase chain reaction (qPCR) analysis. Analysis of Cxcl1, Il6, Ccl20 , and Vcam1 genes in splenocytes from sham ( n = 6) and αIL17A Affibody molecule treated mice ( n = 5) (A-D) . Analysis of Casp3, Cd3e Cxcl1 , and Il6 transcripts in the thoracic aorta from sham ( n = 12) and αIL17A Affibody molecules treated mice ( n = 10-11) (E-H) . Data are presented as Median with IQR. NS, Not significant.
    Figure Legend Snippet: Effects of Affibody molecule against IL17A on gene expression in splenocytes and thoracic aorta from ApoE −/− mice. mRNA levels were assessed by quantitative real-time reverse transcription polymerase chain reaction (qPCR) analysis. Analysis of Cxcl1, Il6, Ccl20 , and Vcam1 genes in splenocytes from sham ( n = 6) and αIL17A Affibody molecule treated mice ( n = 5) (A-D) . Analysis of Casp3, Cd3e Cxcl1 , and Il6 transcripts in the thoracic aorta from sham ( n = 12) and αIL17A Affibody molecules treated mice ( n = 10-11) (E-H) . Data are presented as Median with IQR. NS, Not significant.

    Techniques Used: Expressing, Reverse Transcription, Polymerase Chain Reaction



    Similar Products

    murine recombinant il17a  (R&D Systems)
    93
    R&D Systems murine recombinant il17a
    In vitro efficacy of Affibody molecules in blocking <t>IL17A</t> induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Murine Recombinant Il17a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine recombinant il17a/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    murine recombinant il17a - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    recombinant murine il17a protein  (PeproTech)
    90
    PeproTech recombinant murine il17a protein
    In vitro efficacy of Affibody molecules in blocking <t>IL17A</t> induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Recombinant Murine Il17a Protein, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant murine il17a protein/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant murine il17a protein - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant murine il17a  (PeproTech)
    90
    PeproTech recombinant murine il17a
    In vitro efficacy of Affibody molecules in blocking <t>IL17A</t> induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Recombinant Murine Il17a, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant murine il17a/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant murine il17a - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    murine recombinant il17a  (PeproTech)
    90
    PeproTech murine recombinant il17a
    In vitro efficacy of Affibody molecules in blocking <t>IL17A</t> induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Murine Recombinant Il17a, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine recombinant il17a/product/PeproTech
    Average 90 stars, based on 1 article reviews
    murine recombinant il17a - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    murine recombinant il17a proteins  (R&D Systems)
    93
    R&D Systems murine recombinant il17a proteins
    In vitro efficacy of Affibody molecules in blocking <t>IL17A</t> induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).
    Murine Recombinant Il17a Proteins, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine recombinant il17a proteins/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    murine recombinant il17a proteins - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro efficacy of Affibody molecules in blocking IL17A induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

    doi: 10.3389/fcvm.2022.831039

    Figure Lengend Snippet: In vitro efficacy of Affibody molecules in blocking IL17A induced responses in human aortic smooth muscle cells (SMCs) and mouse NIH/3T3 fibroblast cells. ELISA data showing the release of CXCL1 and IL6 into the medium (24 h) induced by increasing concentration of recombinant IL17A in human SMCs ( n = 4) (A,B) and CXCL1 in mouse 3T3 fibroblast cells ( n = 4) (E) . Human SMCs were stimulated with 5 ng/ml recombinant IL17A and without or with increasing concentrations of human Affibody molecules against IL17A and release of CXCL1 and IL6 (24 h) was assessed by ELISA ( n = 3) (C,D) . Mouse NIH/3T3 fibroblast cells were stimulated with 25 ng/ml recombinant IL17A and without or with increasing concentration of Affibody molecule against mouse IL17A and release of CXCL1 (24 h) was assessed by ELISA ( n = 5) (F) . Data is presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control or as mentioned in graph (vs. IL17A).

    Article Snippet: The next day, the media was replaced with fresh antibiotics free medium, and cells were treated with different concentrations of human or murine recombinant IL17A (R&D systems, USA) and cultured in the presence or absence of human or murine Affibody molecule at different concentrations to block IL17A (Affibody AB, Sweden), for 24 h. Unstimulated cells served as reference.

    Techniques: In Vitro, Blocking Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay, Recombinant, Control

    Effect of Affibody molecule targeting IL17A in atherosclerotic lesion development in ApoE −/− mice. Quantification of lesion size (%) in the aortic arch (A) and brachiocephalic artery (B) of control mice and αIL17A Affibody molecule treated mice. Quatification of lesion areas (μm 2 ) in the aortic root (C) . Representative Oil Red O immunostainings from the aortic root of control (D) and mice treated with αIL17A Affibody molecule (E) . Data are presented as Median with IQR.

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

    doi: 10.3389/fcvm.2022.831039

    Figure Lengend Snippet: Effect of Affibody molecule targeting IL17A in atherosclerotic lesion development in ApoE −/− mice. Quantification of lesion size (%) in the aortic arch (A) and brachiocephalic artery (B) of control mice and αIL17A Affibody molecule treated mice. Quatification of lesion areas (μm 2 ) in the aortic root (C) . Representative Oil Red O immunostainings from the aortic root of control (D) and mice treated with αIL17A Affibody molecule (E) . Data are presented as Median with IQR.

    Article Snippet: The next day, the media was replaced with fresh antibiotics free medium, and cells were treated with different concentrations of human or murine recombinant IL17A (R&D systems, USA) and cultured in the presence or absence of human or murine Affibody molecule at different concentrations to block IL17A (Affibody AB, Sweden), for 24 h. Unstimulated cells served as reference.

    Techniques: Control

    Blood and morphometric parameters <xref ref-type= a and T cell subsets in spleen b ." width="100%" height="100%">

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

    doi: 10.3389/fcvm.2022.831039

    Figure Lengend Snippet: Blood and morphometric parameters a and T cell subsets in spleen b .

    Article Snippet: The next day, the media was replaced with fresh antibiotics free medium, and cells were treated with different concentrations of human or murine recombinant IL17A (R&D systems, USA) and cultured in the presence or absence of human or murine Affibody molecule at different concentrations to block IL17A (Affibody AB, Sweden), for 24 h. Unstimulated cells served as reference.

    Techniques: Control

    Affibody molecule against IL17A reduces plasma levels of inflammatory and/or atherosclerosis-associated proteins in ApoE −/− mice. The Volcano plot shows fold changes (FC) and p -values of differentially altered plasma proteins analyzed by olink proteomics, in mice treated with αIL17A Affibody molecule ( n = 11) compared to sham ( n = 12) (A) . The p -values are presented on log10 scale while the FCs were calculated from linearized normalized protein expression (NPX) values and presented on log2 scale. Positive log2 fold change values correspond to higher protein levels and negative values correspond to reduced protein levels in mice treated with αIL17A Affibody molecule. The horizontal dotted line reflects the cut-off for statistical significance ( p < 0.05). Blue circles highlight proteins with a significant decrease ( p < 0.05) and red circles highlight proteins with a significant increase ( p < 0.05). Gray circles represent proteins with no statistical significance. Correlation between the plasma concentration of CXCL1 protein and the area of aortic root lesion in atherosclerotic prone ApoE −/− mice ( n = 8) (B) .

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

    doi: 10.3389/fcvm.2022.831039

    Figure Lengend Snippet: Affibody molecule against IL17A reduces plasma levels of inflammatory and/or atherosclerosis-associated proteins in ApoE −/− mice. The Volcano plot shows fold changes (FC) and p -values of differentially altered plasma proteins analyzed by olink proteomics, in mice treated with αIL17A Affibody molecule ( n = 11) compared to sham ( n = 12) (A) . The p -values are presented on log10 scale while the FCs were calculated from linearized normalized protein expression (NPX) values and presented on log2 scale. Positive log2 fold change values correspond to higher protein levels and negative values correspond to reduced protein levels in mice treated with αIL17A Affibody molecule. The horizontal dotted line reflects the cut-off for statistical significance ( p < 0.05). Blue circles highlight proteins with a significant decrease ( p < 0.05) and red circles highlight proteins with a significant increase ( p < 0.05). Gray circles represent proteins with no statistical significance. Correlation between the plasma concentration of CXCL1 protein and the area of aortic root lesion in atherosclerotic prone ApoE −/− mice ( n = 8) (B) .

    Article Snippet: The next day, the media was replaced with fresh antibiotics free medium, and cells were treated with different concentrations of human or murine recombinant IL17A (R&D systems, USA) and cultured in the presence or absence of human or murine Affibody molecule at different concentrations to block IL17A (Affibody AB, Sweden), for 24 h. Unstimulated cells served as reference.

    Techniques: Expressing, Concentration Assay

    Effects of Affibody molecule against IL17A on gene expression in splenocytes and thoracic aorta from ApoE −/− mice. mRNA levels were assessed by quantitative real-time reverse transcription polymerase chain reaction (qPCR) analysis. Analysis of Cxcl1, Il6, Ccl20 , and Vcam1 genes in splenocytes from sham ( n = 6) and αIL17A Affibody molecule treated mice ( n = 5) (A-D) . Analysis of Casp3, Cd3e Cxcl1 , and Il6 transcripts in the thoracic aorta from sham ( n = 12) and αIL17A Affibody molecules treated mice ( n = 10-11) (E-H) . Data are presented as Median with IQR. NS, Not significant.

    Journal: Frontiers in Cardiovascular Medicine

    Article Title: Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice

    doi: 10.3389/fcvm.2022.831039

    Figure Lengend Snippet: Effects of Affibody molecule against IL17A on gene expression in splenocytes and thoracic aorta from ApoE −/− mice. mRNA levels were assessed by quantitative real-time reverse transcription polymerase chain reaction (qPCR) analysis. Analysis of Cxcl1, Il6, Ccl20 , and Vcam1 genes in splenocytes from sham ( n = 6) and αIL17A Affibody molecule treated mice ( n = 5) (A-D) . Analysis of Casp3, Cd3e Cxcl1 , and Il6 transcripts in the thoracic aorta from sham ( n = 12) and αIL17A Affibody molecules treated mice ( n = 10-11) (E-H) . Data are presented as Median with IQR. NS, Not significant.

    Article Snippet: The next day, the media was replaced with fresh antibiotics free medium, and cells were treated with different concentrations of human or murine recombinant IL17A (R&D systems, USA) and cultured in the presence or absence of human or murine Affibody molecule at different concentrations to block IL17A (Affibody AB, Sweden), for 24 h. Unstimulated cells served as reference.

    Techniques: Expressing, Reverse Transcription, Polymerase Chain Reaction